Drug developers often operate under a hyper-conservative perception of FDA requirements, avoiding novel approaches even when regulators might encourage them. This anticipatory compliance, driven by risk aversion, becomes a greater constraint than the regulations themselves, slowing down innovation and increasing costs.

Biotech companies are incentivized to own the entire intellectual property for a drug, from delivery to molecule. This leads to endless litigation and siloed innovation, preventing the combination of "best-in-class" components from different companies and ultimately slowing progress for patients.

Our ability to generate and test therapeutic hypotheses in silico is rapidly outpacing the slow, expensive conventional clinical trial system. Without regulatory reform, the pipeline of promising drugs will remain stuck, preventing breakthroughs from reaching patients. The science is solvable; the system is not.

The dominant biotech VC model incentivizes startups to act like real estate developers: build an asset to a certain stage (e.g., early clinical data) and then sell it to a large pharmaceutical company. This focus on short-term exits discourages the long-term, ambitious company-building required for revolutionary platforms.

The primary barrier to implementing AI for antibody developability isn't the tech, which has been available for over a decade. MIT's Bernhard Trout states the real failure point is a lack of sustained corporate commitment, as key personnel are frequently reassigned to other projects, causing initiatives to stall.

The biggest competitor for a new technology in pharma quality control isn't another new technology, but established methods. The industry is highly change-averse due to regulatory risk, so any innovation must offer a value proposition that is orders of magnitude better, not just incremental, to overcome this inertia.

Disruptive ideas within large companies trigger an organizational "immune system response." Just as biological antibodies attack foreign invaders, the corporate structure, designed for predictability, attacks novel ideas, preventing radical innovation from taking root.

A massive disconnect exists where scientific breakthroughs are accelerating, yet the biotech market is in a downturn, with many companies trading below cash. This paradox highlights structural and economic failures within the industry, rather than a lack of scientific progress. The core question is why the business is collapsing while the technology is exploding.

With clinical development cycles lasting 7-10 years, junior team members rarely see a project to completion. Their career incentive becomes pushing a drug to the next stage to demonstrate progress, rather than ensuring its ultimate success. This pathology leads to deferred problems and siloed knowledge.